Meeting
2018 ASCO Annual Meeting
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
Authors
Xiaotong Li
Yale University, New Haven, CT
Xiaotong Li , Sarah Warren , Vasiliki Pelekanou , Vikram Wali , Alessandra Cesano , Mingdong Liu , Patrick Danaher , Nathan Elliott , Zeina A. Nahleh , Daniel F. Hayes , Gabriel N. Hortobagyi , William E. Barlow , Christos Hatzis , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 578)
DOI
10.1200/JCO.2018.36.15_suppl.578
Abstract #
578
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.
First Author: Vasiliki Pelekanou
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2017 ASCO Annual Meeting
A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
First Author: Sibylle Loibl